These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1058 related articles for article (PubMed ID: 31319389)

  • 1. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
    Ajani JA; D'Amico TA; Bentrem DJ; Chao J; Corvera C; Das P; Denlinger CS; Enzinger PC; Fanta P; Farjah F; Gerdes H; Gibson M; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Johung KL; Keswani RN; Kleinberg LR; Leong S; Ly QP; Matkowskyj KA; McNamara M; Mulcahy MF; Paluri RK; Park H; Perry KA; Pimiento J; Poultsides GA; Roses R; Strong VE; Wiesner G; Willett CG; Wright CD; McMillian NR; Pluchino LA
    J Natl Compr Canc Netw; 2019 Jul; 17(7):855-883. PubMed ID: 31319389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esophageal and esophagogastric junction cancers, version 1.2015.
    Ajani JA; D'Amico TA; Almhanna K; Bentrem DJ; Besh S; Chao J; Das P; Denlinger C; Fanta P; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Jasperson K; Keswani RN; Kleinberg LR; Korn WM; Leong S; Lockhart AC; Mulcahy MF; Orringer MB; Posey JA; Poultsides GA; Sasson AR; Scott WJ; Strong VE; Varghese TK; Washington MK; Willett CG; Wright CD; Zelman D; McMillian N; Sundar H;
    J Natl Compr Canc Netw; 2015 Feb; 13(2):194-227. PubMed ID: 25691612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
    Ajani JA; D'Amico TA; Bentrem DJ; Cooke D; Corvera C; Das P; Enzinger PC; Enzler T; Farjah F; Gerdes H; Gibson M; Grierson P; Hofstetter WL; Ilson DH; Jalal S; Keswani RN; Kim S; Kleinberg LR; Klempner S; Lacy J; Licciardi F; Ly QP; Matkowskyj KA; McNamara M; Miller A; Mukherjee S; Mulcahy MF; Outlaw D; Perry KA; Pimiento J; Poultsides GA; Reznik S; Roses RE; Strong VE; Su S; Wang HL; Wiesner G; Willett CG; Yakoub D; Yoon H; McMillian NR; Pluchino LA
    J Natl Compr Canc Netw; 2023 Apr; 21(4):393-422. PubMed ID: 37015332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant (postoperative) therapy for esophageal cancer.
    Ku GY; Ilson DH
    Thorac Surg Clin; 2013 Nov; 23(4):525-33. PubMed ID: 24199702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
    BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
    Cohen DJ; Leichman L
    J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis.
    Lin S; Liu T; Chen J; Li G; Dang J
    PLoS One; 2021; 16(6):e0252751. PubMed ID: 34086780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenocarcinoma of the esophagogastric junction.
    Jenkins TD; Friedman LS
    Dig Dis; 1999; 17(3):153-62. PubMed ID: 10697664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unanswered questions in the management of gastroesophageal junction adenocarcinoma: an overview from the medical oncologist's perspective.
    Shah MA
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92.
    Becerra CR; Hanna N; McCollum AD; Becharm N; Timmerman RD; DiMaio M; Kesler KA; Yu M; Yan T; Choy H
    J Thorac Oncol; 2013 Nov; 8(11):1425-9. PubMed ID: 24084441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative and adjuvant therapies for upper gastrointestinal cancers.
    Varadhachary G; Ajani JA
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):719-25. PubMed ID: 16111471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment approaches to esophagogastric junction tumors.
    Kurokawa Y; Sasako M; Doki Y
    Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: A single-center experience from India with a brief review of the literature.
    Krishnamurthy A; Mohanraj N; Radhakrishnan V; John A; Selvaluxmy G
    Indian J Cancer; 2017; 54(4):646-651. PubMed ID: 30082551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic Submucosal Dissection for Adenocarcinomas of the Esophagogastric Junction.
    Nagami Y; Ominami M; Otani K; Hosomi S; Tanaka F; Taira K; Kamata N; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    Digestion; 2018; 97(1):38-44. PubMed ID: 29393168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?
    Cartwright E; Keane FK; Enzinger PC; Hong T; Chau I
    Am Soc Clin Oncol Educ Book; 2018 May; 38():280-291. PubMed ID: 30231360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of esophagogastric junction carcinoma: an unsolved debate.
    Orditura M; Galizia G; Lieto E; De Vita F; Ciardiello F
    World J Gastroenterol; 2015 Apr; 21(15):4427-31. PubMed ID: 25914451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
    Moehler M; Baltin CT; Ebert M; Fischbach W; Gockel I; Grenacher L; Hölscher AH; Lordick F; Malfertheiner P; Messmann H; Meyer HJ; Palmqvist A; Röcken C; Schuhmacher C; Stahl M; Stuschke M; Vieth M; Wittekind C; Wagner D; Mönig SP
    Gastric Cancer; 2015 Jul; 18(3):550-63. PubMed ID: 25192931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
    Khan U; Shah MA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
    [No Abstract]   [Full Text] [Related]  

  • 20. Distant Oncologic Outcome of Patients with Locally Advanced Unresectable and Metastatic Esophageal Cancer after Multimodality Treatment.
    Anghel R; Constantinoiu S; Bacinschi X; Gales L; Toma RV; Trifanescu O
    Chirurgia (Bucur); 2018; 113(1):116-122. PubMed ID: 29509538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 53.